此轮涨势主要受两方面利好因素推动：首先，燃石医学近期在多个国际学术会议上发布了重要研究成果，聚焦DNA/RNA联合检测和低丰度循环肿瘤DNA（ctDNA）检测技术。公司与阿斯利康合作开发的ctDNA检测产品OncoCompass® Plus Prime表现出高度准确性和可靠性，为双方在癌症诊断领域的深入合作奠定了基础。其次，公司的OncoGuide OncoScreen Plus CDx系统已获得日本厚生劳动省的制造和销售批准，作为阿斯利康AKT抑制剂Truqap的伴随诊断产品，有望在明年上半年进入日本医保体系，为公司开拓日本市场带来新机遇。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.